NCT00338182 is a Phase 1 clinical trial of AZD1152 part A in Tumors, sponsored by AstraZeneca.

Who is sponsoring NCT00338182?

NCT00338182 is sponsored by AstraZeneca.

What drugs are being tested in NCT00338182?

Interventions in NCT00338182: AZD1152 part A, AZD1152 part B.

Is NCT00338182 still recruiting?

NCT00338182 is currently completed. Last updated 24 April 2017.

Last reviewed 2017-04-24 · How we verify

NCT00338182

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

AZD1152 in Patients With Advanced Solid Malignancies

Completed Phase 1 Last updated 24 April 2017

What this trial tests

Phase 1 trial testing AZD1152 part A in Tumors in 43 participants. Completed in 1 March 2017.

Timeline

23 May 2006

Primary endpoint
6 June 2008

1 March 2017

Quick facts

Lead sponsor	AstraZeneca
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	43
Start date	23 May 2006
Primary completion	6 June 2008
Estimated completion	1 March 2017
Sites	2 locations across United States

Drugs / interventions tested

AZD1152 part A — full drug profile →
AZD1152 part B — full drug profile →

Conditions studied

Tumors — all drugs for Tumors →

Sponsor

AstraZeneca — full company profile →

Who can join

Adults 18 to 130, any sex, with Tumors. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The primary purpose of this protocol is to investigate the safety and tolerability of AZD1152 when given as a continuous 48-hour infusion every 14 days and as a 2-hour infusion for 2 consecutive days every 14 days in patients with advanced solid malignancies.

Publications & conference data

7 peer-reviewed publications reference this trial (live from Europe PMC):

Aurora Kinase B Inhibition: A Potential Therapeutic Strategy for Cancer.
Borah NA, Reddy MM. · · 2021 · cited 117× · PMID 33915740 · DOI 10.3390/molecules26071981
The two sides of chromosomal instability: drivers and brakes in cancer.
Hosea R, Hillary S, Naqvi S, Wu S, et al · · 2024 · cited 102× · PMID 38553459 · DOI 10.1038/s41392-024-01767-7
Second-Generation Antimitotics in Cancer Clinical Trials.
Novais P, Silva PMA, Amorim I, Bousbaa H. · · 2021 · cited 37× · PMID 34371703 · DOI 10.3390/pharmaceutics13071011
Aurora B Inhibitors as Cancer Therapeutics.
Kovacs AH, Zhao D, Hou J. · · 2023 · cited 32× · PMID 37110619 · DOI 10.3390/molecules28083385
Aurora B: A new promising therapeutic target in cancer.
Chieffi P. · · 2018 · cited 29× · PMID 29862159 · DOI 10.5582/irdr.2018.01018
Seize the engine: Emerging cell cycle targets in breast cancer.
Fuentes-Antrás J, Bedard PL, Cescon DW. · · 2024 · cited 21× · PMID 38264947 · DOI 10.1002/ctm2.1544
Cell cycle inhibitors activate the hypoxia-induced DDX41/STING pathway to mediate antitumor immune response in liver cancer.
Wong PY, Chan CYK, Xue HDG, Goh CC, et al · · 2024 · cited 7× · PMID 39388278 · DOI 10.1172/jci.insight.170532

Verify or expand the search:

Other recruiting trials for Tumors

Currently open trials in the same condition.

NCT05697406 — HP Pyruvate MRI in Cancers · Phase 1, PHASE2 · recruiting
NCT05103358 — Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 G · Phase 2 · active not recruiting
NCT05103969 — Cohort of Tumors With POLE/D1 Mutation · recruiting
NCT04950959 — XACT ACE Observational Registry · recruiting
NCT04341181 — ProTarget - A Danish Nationwide Clinical Trial on Targeted Cancer Treatment Based on Genomic Profiling · Phase 2 · recruiting

Other AstraZeneca trials

Trials by the same sponsor.

NCT06998095 — Tezepelumab (Tezspire) Regulatory Postmarketing Surveillance in Korea · not yet recruiting
NCT07431775 — Saphnelo Use in Females of Child-bearing Potential · not yet recruiting
NCT07516184 — Explore the Diagnostic Value of Bronchodilation Test With Portable Oscillometry in Asthma Diagnosis · NA · not yet recruiting
NCT07279935 — Osimertinib Combined With Chemotherapy in Patients Who Had Distant Recurrence After Adjuvant Osimertinib for EGFRm Resec · Phase 4 · not yet recruiting
NCT07279948 — A Single-arm Observational Study to Characterize the Demographic, Clinical Features and Outcomes of a Brazilian Cohort o · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00338182 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by AstraZeneca
Last refreshed: 24 April 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00338182.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing